MCID: VRL010
MIFTS: 60

Viral Hepatitis malady

Categories: Infectious diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases, Liver diseases, Immune diseases, Skin diseases

Aliases & Classifications for Viral Hepatitis

Aliases & Descriptions for Viral Hepatitis:

Name: Viral Hepatitis 12 52 3 14 69
Hepatitis, Viral, Animal 42 69
Unspecified Viral Hepatitis with Hepatic Coma 12
Viral Hepatitis with Hepatic Coma 12
Animal Viral Hepatitis 12
Human Viral Hepatitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1884
MeSH 42 D006524
UMLS 69 C0019194

Summaries for Viral Hepatitis

Disease Ontology : 12 A hepatitis that involves viral infection causing inflammation of the liver.

MalaCards based summary : Viral Hepatitis, also known as hepatitis, viral, animal, is related to alopecia and fulminant viral hepatitis. An important gene associated with Viral Hepatitis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are PEDF Induced Signaling and Toll-like Receptor Signaling Pathway. The drugs Ribavirin and Adefovir Dipivoxil have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

CDC : 3 Learn more about the ABCs of Hepatitis.

Wikipedia : 71 Viral hepatitis is liver inflammation due to a viral infection. It may present in acute (recent... more...

Related Diseases for Viral Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Viral Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 221)
id Related Disease Score Top Affiliating Genes
1 alopecia 29.3 ABCB7 GGT1 GPT SLC17A5
2 fulminant viral hepatitis 12.1
3 hepatitis a 11.7
4 hepatitis c 11.3
5 non-a-e hepatitis 11.2
6 hepatitis e 11.1
7 porphyria cutanea tarda 11.1
8 hepatitis 11.0
9 epstein-barr virus hepatitis 10.7
10 hepatitis d 10.5
11 hepatitis b 10.5
12 congenital dyserythropoietic anemia 10.3 ALB TNF
13 ebstein anomaly 10.3 GGT1 SLC17A5
14 nondystrophic myotonia 10.3 ALB F2
15 gastric neuroendocrine tumor type 1 10.3 GPT SLC17A5
16 hepatocellular carcinoma 10.3
17 rosacea 10.3 ALB GPT SLC17A5
18 mixed hepatoblastoma 10.3 F2 IFNA2 TGFB1
19 pulpitis 10.3 F2 SLC17A5 TNF
20 low anorectal malformation 10.3 F2 IFNA1 TNF
21 bladder sarcoma 10.3 ALB GPT TNF
22 rete testis adenoma 10.3 AFP SERPINA1
23 pontine hemorrhage 10.3 AFP SERPINA1
24 pyelitis 10.3 ALB F2 GPT
25 atrophic vulva 10.3 ALB F2 TGFB1
26 angelucci's syndrome 10.2 AFP ALB F2
27 capillary hemangioma 10.2 AFP ALB F2
28 anal fistula 10.2 ALB F2 SLC17A5
29 alcoholic gastritis 10.2 AFP ALB F2
30 female infertility of uterine origin 10.2 ALB F2 GPT SLC17A5
31 ringed hair 10.2 GGT1 GPT
32 kohler's disease 10.2 ALB F2 GPT SLC17A5
33 retinal arterial macroaneurysm with supravalvular pulmonic stenosis 10.2 ALB F2 GPT SLC17A5
34 acute monocytic leukemia 10.2 ALB F2 GPT SLC17A5
35 heart aneurysm 10.2 ALB F2 GGT1
36 klinefelter's syndrome 10.2 AFP ALB SERPINA1
37 infiltrating ureter transitional cell carcinoma 10.2 ALB F2 SLC17A5 TNF
38 familial progressive hyperpigmentation 10.2 F2 GPT
39 pseudo-meigs syndrome 10.2 FAS FASLG TNF
40 basilar artery insufficiency 10.2 F2 IFNA1 IFNA2 TGFB1
41 testicular trophoblastic tumor 10.2 AFP GGT1 SERPINA1
42 liver inflammatory pseudotumor 10.2 ALB TGFB1 TNF
43 acute necrotizing encephalitis 10.2 ALB GGT1 TGFB1
44 patent foramen ovale 10.2 ALB GPT TGFB1
45 gastrointestinal adenoma 10.2 ALB F2 GGT1 GPT
46 sclerosing adenosis of breast 10.2 ALB F2 TGFB1 TNF
47 chronic conjunctivitis 10.2
48 bile duct adenocarcinoma 10.2 ALB CD40LG
49 focal epithelial hyperplasia 10.2 AFP ALB SERPINA1
50 asbestosis 10.2 ALB F2 TNF

Graphical network of the top 20 diseases related to Viral Hepatitis:



Diseases related to Viral Hepatitis

Symptoms & Phenotypes for Viral Hepatitis

GenomeRNAi Phenotypes related to Viral Hepatitis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 TNFRSF1A CD40LG F2 FAS TGFB1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CD40LG F2 FAS FASLG TGFB1 TNF

MGI Mouse Phenotypes related to Viral Hepatitis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 ABCB7 AFP ALB CD40LG F2 FAS
2 mortality/aging MP:0010768 10.13 ALB CD40LG F2 FAS FASLG FGL2
3 endocrine/exocrine gland MP:0005379 10.09 GGT1 TGFB1 TNF TNFRSF1A AFP ALB
4 digestive/alimentary MP:0005381 10.06 F2 FAS FASLG HFE TGFB1 TNF
5 liver/biliary system MP:0005370 10.02 ABCB7 AFP ALB FAS FASLG HFE
6 integument MP:0010771 9.97 CD40LG F2 FAS FASLG GGT1 TGFB1
7 neoplasm MP:0002006 9.7 AFP ALB FAS FASLG TGFB1 TNF
8 renal/urinary system MP:0005367 9.5 ALB CD40LG FAS FASLG GGT1 TGFB1
9 reproductive system MP:0005389 9.28 F2 FAS FASLG GGT1 TGFB1 TNF

Drugs & Therapeutics for Viral Hepatitis

Drugs for Viral Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 676)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
2
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142340-99-6 60871
3
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
4
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
5
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
6
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147127-20-6 464205
7
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
8
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
10
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
11
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
12
Aluminum hydroxide Approved Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
13
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
14
Amantadine Approved Phase 4,Phase 3,Phase 2 768-94-5 2130
15
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
16
Isoniazid Approved Phase 4,Phase 2,Phase 3 54-85-3 3767
17
Pyrazinamide Approved Phase 4 98-96-4 1046
18
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
19
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
20
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
21
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
22
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
23
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
24
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1 76-99-3 4095
25
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 83-43-2 6741
27
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-24-8 5755
28
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
29
Benzocaine Approved Phase 4,Phase 2,Phase 3 1994-09-7, 94-09-7 2337
30
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
31
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
32
Ethiodized oil Approved Phase 4,Phase 3,Phase 2 8008-53-5
33
Pentoxifylline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6493-05-6 4740
34
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
35
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
36
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
37
Insulin Glargine Approved Phase 4 160337-95-1
38
Insulin-glulisine Approved Phase 4 207748-29-6
39
Zinc Approved Phase 4,Phase 2,Phase 3 7440-66-6 32051 23994
40
Ledipasvir Approved Phase 4,Phase 3,Phase 2,Phase 1 1256388-51-8 67505836
41
Sofosbuvir Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1190307-88-0 45375808
42
Simeprevir Approved Phase 4,Phase 3,Phase 2,Phase 1 923604-59-5 66576988
43
Interferon alfacon-1 Approved Phase 4,Phase 3,Phase 2 118390-30-0 9554198
44
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
45
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 376348-65-1 3002977
46
Thymalfasin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 62304-98-7
47
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154598-52-4 64139
48 Simethicone Approved Phase 4,Phase 3
49
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1 30516-87-1 35370
50
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696

Interventional clinical trials:

(show top 50) (show all 3489)
id Name Status NCT ID Phase
1 Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG) Unknown status NCT01311674 Phase 4
2 Ribavirin, Its Dosing Regime Unknown status NCT00484328 Phase 4
3 Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01829685 Phase 4
4 Antiviral Efficacy of Switching to ETV Plus TDF Unknown status NCT01597934 Phase 4
5 Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B Unknown status NCT00597259 Phase 4
6 Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4
7 Hepatitis C in Renal Transplant Recipients Unknown status NCT02108301 Phase 4
8 A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults Unknown status NCT02203357 Phase 4
9 Tenofovir in Late Pregnancy to Prevent Vertical Transmission of Hepatitis B Virus Unknown status NCT01488526 Phase 4
10 PCV13 + Hepatitis A Vaccine for Adults Unknown status NCT01926860 Phase 4
11 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4
12 Combination Hepatitis A and B Vaccine to Induce Immunity in Non-responders Unknown status NCT01126853 Phase 4
13 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4
14 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4
15 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4
16 Adolescents' Response to Hepatitis B Vaccine Booster Dose Unknown status NCT01341275 Phase 4
17 Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine(Hecolin®) Unknown status NCT02189603 Phase 4
18 Efficacy Optimizing Research of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy Unknown status NCT01341743 Phase 4
19 Cellular Immunity in Adult Hepatitis B-vaccinated Serologic Non-responders Unknown status NCT01451801 Phase 4
20 Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C Unknown status NCT01649245 Phase 4
21 Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA) Unknown status NCT00127777 Phase 4
22 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4
23 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4
24 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin Unknown status NCT01025765 Phase 4
25 Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection Unknown status NCT01594905 Phase 4
26 Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy Unknown status NCT01595633 Phase 4
27 A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone Unknown status NCT00354653 Phase 4
28 Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Unknown status NCT01439776 Phase 4
29 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4
30 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4
31 A Two-year Study of Telbivudine in HBeAg Negative Hepatitis Unknown status NCT01521975 Phase 4
32 Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study Unknown status NCT01804387 Phase 4
33 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4
34 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4
35 Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B Unknown status NCT01913431 Phase 4
36 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B Unknown status NCT00917761 Phase 4
37 Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents Unknown status NCT02337127 Phase 4
38 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4
39 Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B Unknown status NCT00921180 Phase 4
40 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4
41 A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin. Unknown status NCT02150291 Phase 4
42 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4
43 Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B Unknown status NCT01926288 Phase 4
44 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4
45 Study of Effects and Safety Between Adefovir Dipivoxil Plus Polyene Phosphatidylcholine Versus Adefovir Dipivoxil Alone in Chronic Hepatitis B Patients Unknown status NCT01436539 Phase 4
46 Prednisolone Priming Study in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4
47 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
48 PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Response(RVR) Unknown status NCT01056172 Phase 4
49 Nutritional Support During Antiviral Therapy for Hepatitis C Unknown status NCT00841243 Phase 4
50 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4

Search NIH Clinical Center for Viral Hepatitis

Cochrane evidence based reviews: hepatitis, viral, animal

Genetic Tests for Viral Hepatitis

Anatomical Context for Viral Hepatitis

MalaCards organs/tissues related to Viral Hepatitis:

39
Liver, Testes, Kidney, T Cells, Thyroid, Monocytes, Bone

Publications for Viral Hepatitis

Articles related to Viral Hepatitis:

(show top 50) (show all 1026)
id Title Authors Year
1
Viral hepatitis status does not affect survival in patients with hepatocellular carcinoma. ( 28042245 )
2017
2
Noninvasive Assessment of Liver Fibrosis Stage Using Ultrasound-Based Shear Wave Velocity Measurements and Serum Algorithms in Patients With Viral Hepatitis B: A Retrospective Cohort Study. ( 28039877 )
2017
3
The future of liver transplantation for viral hepatitis. ( 28052618 )
2017
4
A Joint Society statement for elimination of viral hepatitis. ( 28051786 )
2017
5
VIRAL HEPATITIS IN ABORIGINAL AND TORRES STRAIT ISLANDER COMMUNITIES. ( 27132388 )
2016
6
Viral hepatitis: HCV compartmentalization in HCC: driver, passenger or both? ( 27006254 )
2016
7
Is there an influence of hepatic steatosis on fibrosis and necroinflammation in young patients with chronic viral hepatitis B? ( 27499150 )
2016
8
Use of telehealth to treat and manage chronic viral hepatitis in regional Queensland. ( 27799448 )
2016
9
Viral hepatitis: Indian scenario. ( 27546957 )
2016
10
Viral hepatitis in India: Armed Forces perspective. ( 27546956 )
2016
11
High prevalence of viral hepatitis in a series of splenic marginal zone lymphomas from Romania. ( 27834940 )
2016
12
An updated approach to viral hepatitis E. ( 28078902 )
2016
13
Hepatocellular Carcinoma and Viral Hepatitis in New York City. ( 27585801 )
2016
14
Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia. ( 27933202 )
2016
15
Particularities of associating viral hepatitis with pregnancy and mental disorders. ( 27151687 )
2016
16
Viral hepatitis: Response-guided strategy to reduce DAA duration for hepatitis C. ( 27625193 )
2016
17
Therapeutic Efficacy and Safety of Paeoniae Radix Rubra Formulae in Relieving Hyperbilirubinemia Induced by Viral Hepatitis: A Meta-Analysis. ( 27047379 )
2016
18
RE: Liver Shear-Wave Velocity to Diagnose Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B. ( 27585908 )
2016
19
Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). ( 27599653 )
2016
20
Report from the International Conference on Viral Hepatitis (ICVH), San Francisco, March 2016. ( 27196355 )
2016
21
Viral hepatitis B and C outbreak related to parenteral treatment at an oncological department in Slovakia. ( 26944899 )
2016
22
Combating the wrath of viral hepatitis in India. ( 27834318 )
2016
23
Ly6C(hi) monocytes regulate T cell responses in viral hepatitis. ( 27777980 )
2016
24
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. ( 27506682 )
2016
25
No more excuses: viral hepatitis can be eliminated. ( 27116263 )
2016
26
Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis. ( 27777893 )
2016
27
Viral hepatitis: beginning of the end? ( 27485785 )
2016
28
Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study. ( 27125364 )
2016
29
Joint society statement for the elimination of viral hepatitis. ( 27492055 )
2016
30
Viral hepatitis: A health problem that requires appropriate planning. ( 27131757 )
2016
31
Adsorption of viral particles from the blood plasma of patients with viral hepatitis on nanodiamonds. ( 27599503 )
2016
32
Prevalence and features of chronic viral hepatitis and HIV coinfection in Italian prisons. ( 27189044 )
2016
33
Viral hepatitis: A mouse model of hepatitis A virus infection. ( 27729656 )
2016
34
Viral Hepatitis in Children: A Through E. ( 27975110 )
2016
35
Case-fatality risk of pregnant women with acute viral hepatitis type E: a systematic review and meta-analysis. ( 26939626 )
2016
36
The role of the general practitioner in the screening and clinical management of chronic viral hepatitis in six EU countries. ( 27582629 )
2016
37
Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection. ( 27490638 )
2016
38
Time for Action on Viral Hepatitis. ( 27118226 )
2016
39
Viral hepatitis: 'Immune tolerance' in HBV infection: danger lurks. ( 27625191 )
2016
40
Liver Shear-Wave Velocity and Serum Fibrosis Markers to Diagnose Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B. ( 27134527 )
2016
41
Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination. ( 27620495 )
2016
42
Science in brief: Equine viral hepatitis. ( 27995661 )
2016
43
Interventions to optimise the care continuum for chronic viral hepatitis: a systematic review and meta-analyses. ( 27615026 )
2016
44
The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B. ( 27075801 )
2016
45
Viral hepatitis and immigration: A challenge for the healthcare system. ( 26995326 )
2016
46
Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. ( 27605882 )
2016
47
The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. ( 26337813 )
2016
48
Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection. ( 26833585 )
2016
49
Role of HEV antigen detection in HEV related acute viral hepatitis and acute liver failure. ( 27153108 )
2016
50
Viral Hepatitis and Assisted Reproduction. ( 27821977 )
2016

Variations for Viral Hepatitis

Expression for Viral Hepatitis

Search GEO for disease gene expression data for Viral Hepatitis.

Pathways for Viral Hepatitis

Pathways related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 33)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.57 CD40LG F2 FAS FASLG IFNA1 IFNA2
2
Show member pathways
12.75 FAS FASLG IFNA1 IFNA2 TGFB1 TNF
3
Show member pathways
12.65 FAS FASLG IFNA1 IFNA2 TNF TNFRSF1A
4 12.64 FAS FASLG TGFB1 TNF TNFRSF1A
5
Show member pathways
12.61 CD40LG FAS FASLG IFNA1 IFNA2 TGFB1
6
Show member pathways
12.57 CD40LG FAS FASLG TNF TNFRSF1A
7
Show member pathways
12.56 CD40LG FAS FASLG TNF TNFRSF1A
8
Show member pathways
12.4 FAS FASLG IFNA1 IFNA2 TNF
9
Show member pathways
12.37 CD40LG FAS TGFB1 TNF
10 12.34 CD40LG FAS FASLG IFNA1 TNF TNFRSF1A
11
Show member pathways
12.27 ALB F2 GGT1 TNF
12
Show member pathways
12.26 FAS FASLG TNF TNFRSF1A
13 12.22 FAS FASLG TGFB1 TNF
14
Show member pathways
12.16 CD40LG TGFB1 TNF TNFRSF1A
15 12.14 CD40LG FAS FASLG TNFRSF1A
16
Show member pathways
12.11 FAS FASLG KRT18 TNF TNFRSF1A
17 12.05 IFNA1 IFNA2 TGFB1 TNF TNFRSF1A
18 11.96 AFP ALB SERPINA1 TGFB1
19 11.93 IFNA1 IFNA2 TNF TNFRSF1A
20
Show member pathways
11.76 FAS FASLG TNFRSF1A
21
Show member pathways
11.71 CD40LG FASLG TNF
22 11.7 IFNA2 TGFB1 TNF
23
Show member pathways
11.68 CD40LG TNF TNFRSF1A
24 11.64 CD40LG TGFB1 TNF
25 11.58 SERPINA1 TGFB1 TNF
26
Show member pathways
11.57 CD40LG TNF TNFRSF1A
27 11.42 CD40LG TGFB1 TNF
28 11.37 AFP ALB F2
29
Show member pathways
11.28 CD40LG FAS FASLG TNF TNFRSF1A
30 11.27 FAS FASLG TNF TNFRSF1A
31 11.21 FAS FASLG TNF
32 11.1 FAS FASLG TNF TNFRSF1A
33
Show member pathways
10.62 FAS FASLG TGFB1 TNF TNFRSF1A

GO Terms for Viral Hepatitis

Cellular components related to Viral Hepatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 AFP ALB CD40LG F2 FAS FASLG
2 cell surface GO:0009986 9.73 CD40LG FAS FASLG TGFB1 TNF TNFRSF1A
3 membrane raft GO:0045121 9.67 FAS FASLG TNF TNFRSF1A
4 external side of plasma membrane GO:0009897 9.63 CD40LG F2 FAS FASLG HFE TNF
5 platelet alpha granule lumen GO:0031093 9.5 ALB SERPINA1 TGFB1
6 extracellular space GO:0005615 9.47 AFP ALB CD40LG F2 FASLG GGT1

Biological processes related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.91 FAS TGFB1 TNF TNFRSF1A
2 cellular protein metabolic process GO:0044267 9.88 AFP ALB F2 SERPINA1
3 blood coagulation GO:0007596 9.85 F2 IFNA1 IFNA2 SERPINA1
4 positive regulation of protein phosphorylation GO:0001934 9.81 F2 FAS TGFB1 TNF
5 inflammatory response GO:0006954 9.8 CD40LG FAS IFNA2 TGFB1 TNF TNFRSF1A
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.79 FAS FASLG TNF
7 defense response GO:0006952 9.78 IFNA1 IFNA2 TNF TNFRSF1A
8 cellular response to mechanical stimulus GO:0071260 9.77 FAS TGFB1 TNFRSF1A
9 apoptotic signaling pathway GO:0097190 9.77 FAS FASLG TNF
10 B cell differentiation GO:0030183 9.75 CD40LG IFNA1 IFNA2
11 humoral immune response GO:0006959 9.7 IFNA1 IFNA2 TNF
12 hepatocyte apoptotic process GO:0097284 9.63 FAS KRT18
13 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.62 FAS FASLG
14 acute-phase response GO:0006953 9.61 F2 HFE SERPINA1
15 B cell proliferation GO:0042100 9.58 CD40LG IFNA1 IFNA2
16 positive regulation of ceramide biosynthetic process GO:2000304 9.57 TNF TNFRSF1A
17 death-inducing signaling complex assembly GO:0071550 9.56 TNF TNFRSF1A
18 regulation of establishment of endothelial barrier GO:1903140 9.54 TNF TNFRSF1A
19 regulation of immunoglobulin secretion GO:0051023 9.49 CD40LG TNF
20 positive regulation of mononuclear cell migration GO:0071677 9.46 TGFB1 TNF
21 extrinsic apoptotic signaling pathway via death domain receptors GO:0008625 9.46 FAS FASLG TNF TNFRSF1A
22 necroptotic signaling pathway GO:0097527 9.43 FAS FASLG TNF
23 tumor necrosis factor-mediated signaling pathway GO:0033209 9.43 CD40LG FAS FASLG KRT18 TNF TNFRSF1A
24 inflammatory cell apoptotic process GO:0006925 9.37 FAS FASLG
25 extrinsic apoptotic signaling pathway GO:0097191 9.02 FAS FASLG KRT18 TGFB1 TNF
26 immune response GO:0006955 10.02 CD40LG FAS FASLG TNF TNFRSF1A

Molecular functions related to Viral Hepatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor binding GO:0043120 9.16 FAS TNFRSF1A
2 tumor necrosis factor receptor binding GO:0005164 9.13 CD40LG FASLG TNF
3 cytokine activity GO:0005125 9.1 CD40LG FASLG IFNA1 IFNA2 TGFB1 TNF

Sources for Viral Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....